These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30343277)

  • 21. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. O⁶-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas.
    Yang SH; Lee KS; Yang HJ; Jeon BH; Lee YS; Nam SW; Chung DS; Lee SW; Hong YK
    J Neurooncol; 2012 Jan; 106(2):243-50. PubMed ID: 21792731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma.
    Li M; Dong G; Zhang W; Ren X; Jiang H; Yang C; Zhao X; Zhu Q; Li M; Chen H; Yu K; Cui Y; Song L
    Cancer Sci; 2021 Sep; 112(9):3699-3710. PubMed ID: 34115910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
    Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE
    J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
    Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
    Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
    Lattanzio L; Borgognone M; Mocellini C; Giordano F; Favata E; Fasano G; Vivenza D; Monteverde M; Tonissi F; Ghiglia A; Fillini C; Bernucci C; Merlano M; Lo Nigro C
    Int J Biol Markers; 2015 May; 30(2):e208-16. PubMed ID: 25588856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
    Brandner S; McAleenan A; Kelly C; Spiga F; Cheng HY; Dawson S; Schmidt L; Faulkner CL; Wragg C; Jefferies S; Higgins JPT; Kurian KM
    Neuro Oncol; 2021 Sep; 23(9):1457-1469. PubMed ID: 34467991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
    Xie H; Tubbs R; Yang B
    Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
    Quillien V; Lavenu A; Ducray F; Joly MO; Chinot O; Fina F; Sanson M; Carpentier C; Karayan-Tapon L; Rivet P; Entz-Werle N; Legrain M; Zalcman EL; Levallet G; Escande F; Ramirez C; Chiforeanu D; Vauleon E; Figarella-Branger D
    Oncotarget; 2016 Sep; 7(38):61916-61929. PubMed ID: 27542245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
    Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
    Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
    Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients.
    Hsu CY; Ho HL; Lin SC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):497-504. PubMed ID: 27153440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
    Xie H; Tubbs R; Yang B
    Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.
    Egaña L; Auzmendi-Iriarte J; Andermatten J; Villanua J; Ruiz I; Elua-Pinin A; Aldaz P; Querejeta A; Sarasqueta C; Zubia F; Matheu A; Samprón N
    Sci Rep; 2020 Oct; 10(1):18445. PubMed ID: 33116181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyrosequencing Analysis of
    Panagopoulos I; Gorunova L; Leske H; Niehusmann P; Johannessen LE; Staurseth J; Øino N; Meling TR; Heim S; Micci F; Brandal P
    Cancer Genomics Proteomics; 2018; 15(5):379-385. PubMed ID: 30194078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.
    Villani V; Casini B; Pace A; Prosperini L; Carapella CM; Vidiri A; Fabi A; Carosi M
    Dis Markers; 2015; 2015():604719. PubMed ID: 26347581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.